Author:
García-Infantes F.,Praena J.,Casanovas A.,Mastromarco M.,Aberle O.,Alcayne V.,Altieri S.,Amaducci S.,Amar Es-Sghir H.,Andrzejewski J.,Babiano-Suarez V.,Bacak M.,Balibrea J.,Bennett S.,Bernardes A.P.,Berthoumieux E.,Bosnar D.,Busso M.,Caamaño M.,Calviño F.,Calviani M.,Cano-Ott D.,Castelluccio D.M.,Cerutti F.,Cescutti G.,Chasapoglou S.,Chiaveri E.,Colombetti P.,Colonna N.,Console Camprini P.C.,Coréts G.,Cortés-Giraldo M.A.,Cosentino L.,Cristallo S.,Di Castro M.,Diacono D.,Diakaki M.,Dietz M.,Domingo-Pardo C.,Dressler R.,Dupont E.,Duarn I.,Eleme Z.,Fargier S.,Fernández-Domínguez B.,Finocchiaro P.,Fiore S.,Furman V.,Gawlik-Ramięga A.,Gervino G.,Gilardoni S.,González-Romero E.,Guerrero C.,Gunsing F.,Gustavino C.,Heyse J.,Jenkins D.G.,Jericha E.,Junghans A.,Kadi Y.,Katabuchi T.,Knapova I.,Kokkoris M.,Kopatch Y.,Krtička M.,Kurtulgil D.,Ladarescu I.,Lederer-Woods C.,Lerendegui-Marco J.,Lerner G.,Manna A.,Martínez T.,Masi A.,Massimi C.,Mastinu P.,Atteucci F.,Maugeri E. A.,Mazzone A.,Mendoza E.,Mengoni A.,Michalopoulou V.,Milazzo P. M.,Mucciola R.,Murtas F.,Musacchio-Gonzalez E.,Musumarra A.,Negret A.,Oprea A.,Pérez-Maroto P.,Patronis N.,Pavón-Rodríguez J. A.,Pellegriti M. G.,Perkowski J.,Petrone C.,Piersanti L.,Pirovano E.,Pomp S.,Porras I.,Protti N.,Quesada J. M.,Rauscher T.,Reifarth R.,Ochman D.,Romanets Y.,Romano F.,Rubbia C.,Sánchez A.,Sabaté-Gilarte M.,Schillebeeckx P.,Schumann D.,Sekhar A.,Smith A. G.,Sosnin N. V.,Spelta M.,Stamati M. E.,Tagliente G.,Tarifeño-Saldivia A.,Tarrío D.,Terranova N.,Torres-Sánchez P.,Urlass S.,Valenta S.,Variale V.,Vaz P.,Vescovi D.,Vlachoudis V.,Lastou R.,Wallner A.,Woods P. J.,Wright T.,Žugec P.,
Abstract
Several international agencies recommend the study of new routes and new facilities for producing radioisotopes with application to nuclear medicine. 177Lu is a versatile radioisotope used for therapy and diagnosis (theranostics) of cancer with good success in neuroendocrine tumours that is being studied to be applied to a wider range of tumours. 177Lu is produced in few nuclear reactors mainly by the neutron capture on 176Lu. However, it could be produced at high-intensity celeratorbased neutron facilities. The energy of the neutrons in accelerator-based neutron facilities is higher than in thermal reactors.Thus, experimental data on the 176Yb(n,γ) cross-section in the eV and keV region are mandatory to calculate accurately the production of 177Yb, which beta decays to 177Lu. At present, there are not experimental data available from thermal to 3 keV of the 176Yb(n,γ) cross-section. In addition, there is no data in the resolved resonance region (RRR). This contribution shows the first results of the 176Yb capture measurement performed at the n_TOF facility at CERN.